{"name":"Tobira Therapeutics, Inc.","slug":"tobira-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Tobira Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for liver disease and other serious conditions with significant unmet medical needs. The company's lead product candidate, cenicriviroc, is in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with fibrosis.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":832000,"revenueGrowth":0,"grossMargin":0,"rdSpend":24672000,"netIncome":-49617000,"cash":62431000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE9fenFYWGxqX0J1eWpGRDBlejlEdmxpWTZlVlhnVVRfdzRTWlhCeUwtdzhNUUFBdVhZVjdVOW9Ia3RYb3VVMVJLbW02VlRxd2VsLVB1R19WNnVYUkI5bkFOZzBucFN6emNhaFZz?oc=5","date":"2020-12-10","type":"pipeline","source":"BioSpace","summary":"BioSpace Movers & Shakers, Dec. 11 - BioSpace","headline":"BioSpace Movers & Shakers, Dec. 11","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQczdQUC12SDZ6ODBnWGFlamlvWFVVSWpNd2hQRG1xV0pjSGVfcG50NDBTXzJDTC15ZFItbzVpWUdRZUZfSU1DR1RmVmlVX0RNaHZYSjR3WngtUDhfM3JWQWNid05RNjY0ajJSZ196cFlaazIxSjdnN1Q2RlRaLUlxUktiRmQ?oc=5","date":"2017-11-02","type":"pipeline","source":"BioPharma Dive","summary":"Boehringer’s NASH dash gets a boost from Dicerna - BioPharma Dive","headline":"Boehringer’s NASH dash gets a boost from Dicerna","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxQTGltSGVPNzFDMktpb0tYR2I3Uy1xQktyekhFdmE5MkIzRDdCblZlcXEzV1dCZHF6TXBqUVZaODlMeUtkT0E2UWR3Qi0yT0J5QkhGc0Y1RHFSd3hSOFl6WVp5XzBYV2toSF9DR0RzS3BVc05jTzdtMU9BbGJYVlFOSkpCZmhlak9DZ28xY0I2TE5qMTF6LWlRZ0VZUlFrSXJjVG9pd0hHdVdoUFhWR29ZdDVGVGN0ZjFpMTlvWUE1QlM0R1VKT09iZUhDVjMzcDJlQ2Y3V3F5alRiU2pQMEtNZTdKck14QnNXNmtDWG1YcUFKTHhlQkFKSEZUazNfZGVoWWVQUFlwOHB0VUVrc0JlNm5WalFpU21JSzBhS1NLNjVzdw?oc=5","date":"2017-10-16","type":"pipeline","source":"PR Newswire","summary":"Allergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed Acquisition of Tobira - PR Newswire","headline":"Allergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQTHZIVlRWVHV1UFVJMVNaWFpvdzhmSUJGaFd2NUtyWWNTbWo3QkVxY0FVQzdZSEMxM20xTU9KZl9rNng2Ulo1dlV6bHFnSHg1OG5zSjZKU0ZDakRJNUVSbnVVRXhSMkExajBRd3JDOWtQenlacVlLVHZTdG1wT1VLMjBXcERUanFtaXpNV0JrMGp6VzQ?oc=5","date":"2017-09-22","type":"trial","source":"BioPharma Dive","summary":"Allergan touts new data from failed NASH study - BioPharma Dive","headline":"Allergan touts new data from failed NASH study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPY3pldU1nTWlrMGYxcUJ2S245NHF3Sl81ZnpvWXYwWXpWazhKMW02NTZDWkpRUFJiZlRXanJCRDFiSUJ5SjdZRVotakxoR0M1dmloc2pnUWxYUVdrODB2bENPQ0xkRnlkaWtLeFRDRENRVzZNOThvY1p5aHF2Z0pBWTNZRG1LeEFqOV9sal8zbTFkdGY4UFRnaUZWUEkxRlk2Rm5jYi1DSzRFTW9FUkM0ZEVNNHB1elBFcTJoZVlOZ2tEN2RNNHFtdlRRRkJGc05IcFdQMERQV3hvNlUtYV84ckJHckx6VHZjalpaY0ppZTVmWFphaTBGVXQ5UE4?oc=5","date":"2016-09-21","type":"deal","source":"PR Newswire","summary":"Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH - PR Newswire","headline":"Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOTC01VTA0TmVseDNyZGdtbm9lbU5fVENFZ084aDNOeVVZUFptQXFJczNBQ0UyYzQwbTI5VE03ejJyZlZ0SFpSUTdOQjdaZ1VuVGlYZUVfVWRiNWt1Z29hMW5HeEE2bGh1WnBOTUtwSWNxUUdlRWphaFVHZGdDTWJWVEtweVk2b2RWdmpteVVjRG12MEZDT3FhbQ?oc=5","date":"2016-09-21","type":"pipeline","source":"Yahoo Finance","summary":"Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma - Yahoo Finance","headline":"Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOaXdjUkVEZGU5TFJRckM0cUN2UkVpQWt2eW5sSlU1YlhKRFZjdmRxTlhoZnZWR1lzMWIyYTVrM2ZJSnduR3hmYUE2RDFGQ1FncHJGSVRIWnFreFVtZWl2T2g0V0I1Z0MyQW9rbm9tSnNUeGJQVVdkWnJZdjJFb1dzNTVFaHZMSkxMN1U4b25ZeXpZRWg0ZmloX04xSWo?oc=5","date":"2016-09-20","type":"pipeline","source":"BioPharma Dive","summary":"Allergan pays steep premium for Tobira and NASH drugs - BioPharma Dive","headline":"Allergan pays steep premium for Tobira and NASH drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNU2VZNEZwOFloblFkX3VKOEk4UEl0TEE3cklBd1AtUkFrYktteEdNd0ZNc2ZSU1ItRlE4Umg5RTZkMXMtTHBCaS1mYTBvNGsweFZmRWFNMmlOTTNYOTZzeXNKS3AtdFlGUF9iSjR2RzJmcVpENEFaMXp5aHFhSjcwbk9IRUM0QVFiVGtNa0pFRTJxWEVLa09lUV9YOWdPelRDdEV4WQ?oc=5","date":"2016-09-20","type":"deal","source":"WSJ","summary":"Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal - WSJ","headline":"Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNT2NwX0FuU1lMZlBKUGhzeDI2SnAtRTdCVm1qMmUta2RmcUlNWmlVTlRmVV9PRDlSMjhpbU5feDZJRG9nRnU2b1d4RDAzQTVnc3hzX0ZvTi1qSHRKQnJRYm13d19CeTZXUlFVaFk1dlo0bVFUZzdyeWVfdkREbkxzQmRuempIYXhZejRnUHI5TjR2NjFyYk9lR1kzaVY2eWROOEV0REY4LVNzQ2llVVBNdUwtSWpXbTBubkN6OWk0WVJIbDVod1oyR1V3dXZoeXZpSk1PelpjbkVNSFk?oc=5","date":"2016-09-20","type":"deal","source":"Reuters","summary":"Allergan to buy Tobira in push for fatty liver disease drugs - Reuters","headline":"Allergan to buy Tobira in push for fatty liver disease drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPcHFrcFowU1U3SzdfV2xuZU1UMlkwbm1hSE5nR2RNRzdOa0dreV9Nc0o4R2t5N21lNFBSVzNEUFhmWXZNSXRhMndxM3ZWQl9PSGdGWWlOOVlObmJGaUx0TmphN3ZNbVNQMG9SdGMwYjR2eTJZVWRESHZfU0hHUmU1WDVCZnRMa0NIT2JWc2JNRHZmLWc?oc=5","date":"2016-04-22","type":"pipeline","source":"The Wall Street Transcript","summary":"Interview with the CEO: Tobira Therapeutics Inc. (NASDAQ:TBRA) - The Wall Street Transcript","headline":"Interview with the CEO: Tobira Therapeutics Inc. (NASDAQ:TBRA)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":832000,"revenuePeriod":"2013-12-31","revenueHistory":[{"value":832000,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":24672000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-49617000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":62431000,"cashHistory":[],"totalAssets":65469000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}